St. Jude scientists identified ZMYND8 as a major regulator of CD8+ T-cell exhaustion. Targeting the gene improved immune function and enhanced immunotherapy, offering a potential new strategy to strengthen anti-tumor responses in solid tumors. bit.ly/3TiiMrc

St. Jude has named Charles W.M. Roberts, MD, PhD, internationally recognized physician-scientist and director of the St. Jude Comprehensive Cancer Center, as its seventh president and CEO. The announcement is part of a planned leadership transition. Under his leadership, the Cancer Center has grown in scope and impact, earning the National Cancer Institute’s top “Exceptional” rating in both reviews and the best score in institutional history each time. Dr. Roberts’ background in cancer epigenetics, clinical care and collaborative leadership has helped shape major efforts that connect researchers, clinicians and partner institutions to move discovery forward.

Scientists led a multi-institute collaboration to create PanNDA, a first-of-its-kind atlas mapping proteomes across six neurodegenerative diseases and more than 10,000 brain proteins. PanNDA can be used as a resource to advance diagnosis and treatment. ow.ly/Yk9N50YxEXN

Our researchers, in collaboration with the Medical College of Wisconsin, have discovered how chemokines and G protein-coupled receptors (GPCRs) selectively bind to control how cells move. ow.ly/77Yl50VGpKe